March 10, 2026 10:17 am (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
CEC Gyanesh Kumar faces black flags during Kalighat Temple visit in Kolkata amid TMC’s SIR protests | ‘Arrogance will be shattered’: PM Modi warns Mamata Banerjee over remarks on President Murmu | Bloodbath on Dalal Street! Sensex, Nifty crash amid escalating Middle East conflict | Iran appoints Mojtaba Khamenei as new supreme leader amid Middle East tension | Iranian drone strike near Dubai Intl. Airport's terminal forces emergency flight suspensions | 26-year-old Hindu man killed after Holi altercation with Muslim neighbour in Delhi’s Uttam Nagar; four arrested | Zohran Mamdani defends wife amid scrutiny over her 'support' for Palestinian cause | Explosions rock club in Kolkata’s Paikpara, locals claim bombs were stored inside | Iran conflict: White House says US could achieve ‘Operation Epic Fury’ objectives in 4–6 weeks | Sensex, Nifty tumble as global tensions and Dow selloff rattle Indian markets
Chinese vaccine
Image: Unsplash

Pakistan says China's Sinopharm vaccine not recommended for people aged above 60

| @indiablooms | Feb 11, 2021, at 04:56 pm

The Chinese Sinopharm vaccine for Covid-19, which started being administered in Pakistan recently, is not recommended for people aged over 60, a top official said.

Speaking to reporters in Islamabad, Special Assistant to the Prime Minister on Health Dr Faisal Sultan was quoted as saying by Dawn News that the government's expert committee while considering the preliminary analysis of Sinopharm data had recommended that the vaccine be licensed for people aged 18-60 "at this stage".

"At this stage, the [committee] did not authorise the vaccine for people older than 60," he added.

When contacted by Dawn News about which vaccine would be used for people over 60 instead of Sinopharm's, Dr Sultan said the AstraZeneca vaccine would be used.

"When our Pakistani experts looked at the data, they were reasonably satisfied with the AstraZeneca data but felt that [based] on the presently available numbers for Sinopharm, the data did not justify its usage for those aged over 60," he said.

"The Chinese have also reiterated this restriction," he added.

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.